Breaking News on Global Pharmaceutical Technology & Manufacturing

Ranbaxy buys Biovel to strengthen in biologics and vaccines

20-Jan-2010 - Ranbaxy Laboratories has strengthened its vaccine and biologics manufacturing capabilities by acquiring India-based Biovel Lifesciences.

Pall buys MRT for mini MTPD technology

13-Jan-2010 - Pall says its acquisition of MicroReactor Technologies (MRT) broadens its offering in the $1bn (€689m) a year global biopharmaceutical process development market.

News in brief

API production starts at Evonik's new plant

11-Jan-2010 - Production has begun at the US API plant German chemicals firm Evonik Industries recently bought from drugmaker Eli Lilly.

Luitpold buys PharmaForce for generic injectables

07-Jan-2010 - Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.

Ranbaxy sells China JV and changes strategy

05-Jan-2010 - Ranbaxy Laboratories has sold its Chinese JV, Ranbaxy Guangzhou China Limited (RGCL), as part of a new approach to the country’s rapidly expanding drug market.

Amcor gets US approval for Alcan takeover

05-Jan-2010 - The US Department of Justice (DOJ) has given partial approval for Amcor’s takeover of Alcan after announcing it would now limit its review to Alcan’s Medical Flexible operations.

DMV-Fonterra builds pharma lactose biz with Domo deal

05-Jan-2010 - Ownership of FrieslandCampina Domo’s pharmaceutical lactose business will be transferred to DMV-Fonterra Excipients, the 50/50 JV set up by Domo owner Royal FrieslandCampina and partner Fonterra.

Novartis to acquire Alcon

04-Jan-2010 - Novartis intends to acquire the remaining 75 per cent of Alcon for $39.3bn (€27.3bn), adding to the shares it bought in April 2008 and giving the big pharma control of...

Merck & Co to buy Avecia Biologics

21-Dec-2009 - US drug major Merck & Co will buy into the UK's contract biologics manufacturing sector with the acquisition of Tees Valley-based Avecia Biologics.

Hospira to buy injectables biz from India’s Orchid

21-Dec-2009 - Hospira will pay India’s Orchid Chemicals and Pharmaceuticals approximately $400m (€278m) for its generic injectables business.

Recipharm moves for Cobra to boost biologics capacity

17-Dec-2009 - Swedish CDMO Recipharm will buy privately-owned group Cobra Biomanufacturing to build its presence in the expanding biologics sector.

News in brief

Taro cites Sun’s “conduct at Caraco” ahead of AGM

15-Dec-2009 - Taro Pharmaceutical Industries has warned shareholders about “Sun’s conduct at Caraco” in its latest effort to block the Indian firm’s takeover bid.

EU clears Amcor takeover of Alcan

15-Dec-2009 - Amcor’s takeover of Alcan has been cleared by the European Commission after the Australian company agreed to sell off two pharmaceutical and food packaging plants in Spain.

Amcor prepares for life after Alcan takeover

11-Dec-2009 - Amcor has unveiled its proposed management shake up in preparation for the $2.025bn takeover of Alcan – three days before the European Commission is due to deliver its verdict on...

Watson completes Arrow deal, adding generic Lipitor to US portfolio

07-Dec-2009 - Watson Pharmaceuticals gained US rights to market a generic version of Lipitor (atorvastatin) in 2011 with the acquisition of non-branded drugmaker Arrow Group late last week.

News in brief

Sterling to buy Canadian drug plant

03-Dec-2009 - Australia’s Sterling Products plans to buy a 4,310 sqm pharmaceutical manufacturing plant from a Canadian drugmaker that has fallen victim to the global economic crisis.

News in brief

Merck & Co to close NJ warehouse with loss of 80 jobs

26-Nov-2009 - US drugmaker Merck & Co is to close a New Jersey warehouse owned by recent acquisition Schering-Plough, cutting 80 jobs.

Millipore buys Indian JV

24-Nov-2009 - Millipore has acquired the remaining 60 per cent of its Indian joint venture (JV) to drive growth in the country which it views, along with the other BRICS nations, as...

Emergent buys Baltimore production plant

17-Nov-2009 - US biotech Emergent BioSolutions has bought a manufacturing facility from Maryland’s MdBio Foundation is a bid to expand its production infrastructure.

Six Pfizer-Wyeth R&D sites to close post merger

10-Nov-2009 - Pfizer will close six R&D facilities in the US and the UK, reducing its global capacity by over a third following completion of its acquisition of Wyeth.

News in brief

New Jersey R&D sites vital, says Merck CEO

05-Nov-2009 - US R&D facilities in Rahway and Kenilworth, New Jersey will remain operational as they are vital to the to the newly formed Merck Schering-Plough group, according to CEO Richard Clark....

Lonza cuts 2009 guidance 14% and plans workforce cuts

02-Nov-2009 - Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”

IMS Health looking at buyout bids

22-Oct-2009 - IMS Health has confirmed it is “exploring strategic alternatives” after speculation this week suggested that the market analysis group had received a number of takeover bids.

Lonza withdraws Patheon bid, but still keen on CMOs

20-Oct-2009 - Swiss healthcare services giant Lonza has withdrawn its offer for Canadian CMO Patheon, citing value considerations, rejection of the bid by JLL and the availability of alternatives.

H Lundbeck eschews outsourcing and buys Elaiapharm

20-Oct-2009 - CNS focused drugmaker H Lundbeck says its acquisition of French CMO Elaiapharm represents a cheaper option than third-party manufacturing.